AI-driven drug discovery consulting
Frame the biological question, choose the computational approach and test whether the available data can support a decision before model development begins.
Ardigen equips pharma and biotech teams with the strategic insights needed to derisk and launch successful AI-driven drug discovery programs. Scientists and AI specialists work with your team to align the question, method, data modality, model scope and validation criteria, producing a program design that can move from analysis to a defensible discovery decision.
Why AI in drug discovery fails in the real world
A team may launch a target-prioritization, biomarker, phenotypic profiling or patient-stratification initiative with a credible scientific objective. Months later, the model performs and the outputs look interesting, but the program still cannot decide which target to advance, which signal to validate or which compound to prioritize.
The failure often begins before modeling. The scientific question was framed as an exploration rather than a decision. The method was chosen for familiarity rather than fit to the biology. The available modality did not capture the required biological signal. Validation measured statistical performance without defining what would count as biologically credible evidence.
These are program-design problems. Addressing them early does not guarantee discovery success, but it gives the model a clear decision to support and makes limitations visible before a larger build begins.
What AI readiness consulting evaluates
An engagement starts with the decisions the organization wants AI to support. Ardigen evaluates the proposed use cases against scientific relevance, data availability, technical complexity, governance requirements and expected decision impact. The assessment distinguishes what can begin now from what first needs data remediation, architecture work, clearer ownership or a narrower scope.
Recommendations reflect delivery constraints. The final roadmap assigns each implementation workstream to the service that owns the detailed engineering, data or application work.
From competing ideas to a plan you can fund
AI readiness assessment
We evaluate your data assets, infrastructure, and team capabilities against the requirements of your target use cases. You get a readiness scorecard by data modality and domain, a gap analysis, and a clear view of what is production-ready and what needs work.
Use case feasibility scoring
We score candidate use cases on scientific relevance, data readiness, technical complexity, and expected decision impact. The result is a prioritized portfolio with a rationale for sequencing, not a ranked wish list.
Target architecture design
We blueprint the data and AI architecture your priorities require: what data products need to exist, how they feed model training and inference, and where governance controls belong.
Phased implementation roadmap
We sequence the work with an MVP definition, dependency mapping, investment estimates, and built-in risk mitigation. It delivers early value while building toward the full architecture, so you avoid a multi-year commitment before anything works.
Request an AI readiness assessment.
Concrete, reusable deliverables
Readiness scorecard. A use-case-specific view of data, infrastructure, governance and team readiness with documented evidence and gaps.
Prioritized use-case portfolio. A feasibility-based sequence with the evidence, assumptions and dependencies behind each priority.
Target-state blueprint. A documented view of the data products, model interfaces, controls and integrations required by the selected initiatives.
Governance recommendations. Clear ownership and review requirements for data stewardship, model oversight, access and scientific challenge.
Phased roadmap. An implementation sequence with an MVP, decision gates, dependency map, risks and investment assumptions.
What changes for your discovery program
Investment grounded in evidence
Leadership decisions reflect scientific value, readiness constraints and delivery dependencies.
A sequence you can defend
Science, data, engineering and operations share one rationale for what begins first and what must wait.
Risk caught before it gets expensive
Data gaps, architectural constraints, ownership problems and governance requirements surface while the plan can still change.
Teams pointed the same way
When the priorities are approved, the roadmap can hand off to the specialist page and delivery team that owns each implementation workstream.
Frequently Asked Questions
Is this strategy consulting or implementation consulting?
Both, and the connection is the point. Our consulting practice is structurally tied to delivery across data engineering, AI model development, and platform work. Recommendations are scoped for implementation from the start, and our teams can build what they design. You get a path forward and a partner able to execute it, not a strategy and a list of questions for your next vendor.
What does an AI readiness assessment actually involve?
We assess your data assets by modality and by the quality dimensions your target use cases require, review your infrastructure against scalability and governance needs, and characterize your capabilities across data science, data engineering, and scientific domain expertise.
You receive a readiness scorecard with specific gap findings, not a generic maturity score, and a clear picture of what to remediate before model development begins.
We already have data science teams. How does consulting add value?
Internal teams bring deep domain knowledge but limited bandwidth for structured architectural and feasibility work. We add cross-program experience from many drug discovery organizations, a proven assessment method, and direct access to implementation teams that can act on findings right away. Engagements often unblock decisions that internal teams have deferred behind competing priorities.
How is a consulting engagement scoped and priced?
Scope depends on the number of use cases under assessment, the complexity of your data environment, and the depth of architectural work required. Most start with a bounded readiness assessment, a fixed-scope engagement with a defined timeline, which produces the foundation for a phased roadmap. Investment estimation is part of that roadmap.
When is consulting the right starting point instead of going straight to implementation?
Consulting fits when the path is genuinely unclear: use cases competing for priority, uncertain data readiness, or a pending infrastructure decision. If your use case, data, and architecture are already defined and validated, implementation may be the more direct route. We can help you decide which fits in an initial conversation.
Contact
Schedule a discovery readiness assessment
Not sure your data is ready for the AI initiatives your team is proposing? A structured readiness assessment surfaces the gaps pilots miss, before you commit to a build.
Send us a message and we will contact you back within 48 hours.
Newsletter
Become an insider
Be the first to know about Ardigen’s latest news and get access to our publications, webinars and more!